OBJECTIVETo monitor genotypes and drug-resistance trend of Acinetobacter baumannii (AB) isolated from burn wards.

METHODSTwenty-six strains of AB isolated from wound secretion, venous catheter, and blood were collected from burn patients hospitalized in our burn wards from November 2008 to February 2009, and June to September 2010. Homogeneous genotype analysis was performed with repetitive extragenic palindromic PCR, and drug-resistance rate to 13 antibiotics including amikacin, gentamicin, etc., which were commonly used in clinic, was tested by K-B paper disk diffusion. The data of drug-resistance rate were processed with chi-square test.

RESULTS(1) Sixteen AB strains were multi-drug resistant (MDR), 9 AB strains were pan-drug resistant (PDR). Among all strains, the resistance rate to gentamicin, piperacillin, piperacillin/tazobactam, cefuroxime, cefotaxime, ceftazidime, cefepime, ciprofloxacin, imipenem, and meropenem was respectively higher than 90.00%; the resistance rate against cefoperazone/sulbactam was the lowest (11/26, 42.31%). There were obvious difference among the drug-resistance rates of AB strains to 13 antibiotics (with rates from 42.31% to 100.00%, χ(2) = 97.371, P < 0.05). (2) There were 7 genotypes among 26 AB strains, respectively type A (17), type B (3), type C (2), type D (1), type E (1), type F (1), and type G (1). Out of the 17 AB strains in A genotype, 1 strain was from 2008, 1 strain was from 2009, 15 strains were from 2010, and among them 11 strains were collected from wound secretion and 6 strains were obtained from blood and venous catheter.

CONCLUSIONSAB strains in A genotype are dominant in our burn wards in recent years, which are MDR or PDR to commonly used antibiotics. Cefoperazone/sulbactam is the drug of choice for burn patients with AB infection.